CoV-2 Omicron
Protein is >95% pure as determined SDS-PAGE.
Description
The E.Coli derived recombinant protein contains the Omicron Covid-19 full-length nucleprotein, fused to 6xHis tag at N-terminal migrating at 48 kDa.
Product Specs
In December 2019, a novel coronavirus responsible for causing viral pneumonia, known as 2019-nCoV or COVID-19, emerged in Wuhan, China. The virus was linked to a seafood market. Genomic analysis revealed that 2019-nCoV shares a significant sequence similarity of 87% with the SARS-CoV-2 virus detected in bats in Zhoushan, eastern China, in 2018. Despite some amino acid variations, the receptor-binding domain (RBD) of 2019-nCoV closely resembles that of the 2018 SARS-CoV, indicating its potential to bind to the human ACE2 receptor. In November 2021, the World Health Organization (WHO) designated the Omicron variant as a Variant of Concern. Omicron possesses several mutations that might influence its transmissibility and the severity of the disease it causes.
This recombinant protein, produced in E. coli, encompasses the full-length nucleocapsid protein of the Omicron variant of SARS-CoV-2. It is fused with a 6xHis tag at its N-terminus and has an approximate molecular weight of 48 kDa.
The CoV-2 Omicron protein solution is provided at a concentration of 2.18 mg/ml in a buffer consisting of phosphate-buffered saline (PBS) and 25mM potassium carbonate (K2CO3).
The protein is shipped with ice packs to maintain its stability during transport. Upon receipt, it should be stored at -20°C.
The purity of the protein is greater than 95%, as determined by SDS-PAGE analysis.
HMSDNGPQNQ RNALRITFGG PSDSTGSNQN GEARSKQRRP QGLPNNTASW FTALTQHGKE DLKFPRGQGV PINTNSSPDD QIGYYRRATR RIRGGDGKMK ELSPRWYFYY LGTGPEAGLP YGANKDGIIW VATEGALNTP KDHIGTRNPA NNAAIVLQLP QGTTLPKGFY AEGSRGGSQA SSRSSSRSRN SSRNSTPGSS KRTSPARMAG NGGDAALALL LLDRLNQLES KMSGKGQQQQ GQTVTKKSAA EASKKPRQKRT ATKAYNVTQA FGRRGPEQTQ GNFGDQELIR QGTDYKHWPQ IAQFAPSASA FFGMSRIGME VTPSGTWLTY TGAIKLDDKD PNFKDQVILL NKHIDAYKTF PPTEPKKDKK KKADETQALP QRQKKQQTVT LLPAADLDDF SKQLQQSMSS ADSTQA
Product Science Overview
The Coronavirus 2019 Omicron Full Length Recombinant refers to a recombinant form of the SARS-CoV-2 virus, specifically the Omicron variant. Recombinant viruses are formed when two or more different strains of a virus infect the same host cell and exchange genetic material, resulting in a new hybrid strain. This process is common among coronaviruses and has been observed multiple times during the COVID-19 pandemic .
The Omicron variant of SARS-CoV-2 was first identified in South Africa in November 2021. It quickly spread globally due to its high transmissibility and ability to partially evade immunity from previous infections and vaccinations. Omicron has several sublineages, including BA.1, BA.2, BA.4, and BA.5, each with distinct genetic mutations .
Recombinant variants, such as the Omicron Full Length Recombinant, emerge when different variants co-infect the same individual. During replication, the genetic material from these variants can mix, creating a new recombinant virus. This process is facilitated by the high mutation rate of SARS-CoV-2 and the large number of infections worldwide .
The Omicron Full Length Recombinant retains the spike protein mutations characteristic of the Omicron variant, which are associated with increased transmissibility and immune evasion. These mutations allow the virus to bind more effectively to the ACE2 receptor on human cells, facilitating entry and infection .
The emergence of recombinant variants like the Omicron Full Length Recombinant poses challenges for public health. These variants can potentially combine the most concerning features of their parent strains, such as increased transmissibility and immune evasion. Continuous monitoring and genomic sequencing are essential to detect and understand the impact of these recombinant variants .
